The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-15-1507PMID 27084740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines

  2016cited by this paper
• An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.

  2016cited by this paper
• Cancer Immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  2016influential reference
• Mutant MHC class II epitopes drive therapeutic immune responses to cancer

  2015cited by this paper
• Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

  2015cited by this paper
• Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

  2015cited by this paper
• Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

  2015cited by this paper
• Immunologic correlates in the course of treatment with immunomodulating antibodies.

  2015cited by this paper
• Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

  2015cited by this paper
• The STING pathway and the T cell-inflamed tumor microenvironment.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015influential reference
• Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer

  2015cited by this paper
• Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

  2015influential reference
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.

  2015cited by this paper
• Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

  2015cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014influential reference
• Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.

  2014cited by this paper
• Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014influential reference
• Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

  2014cited by this paper
• Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

  2014cited by this paper
• High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

  2014cited by this paper
• Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

  2014cited by this paper
• CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

  2014cited by this paper
• Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

  2014cited by this paper
• IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

  2014cited by this paper
• Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

  2014cited by this paper
• Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

  2014cited by this paper
• Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

  2014cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• The roles of TGFβ in the tumour microenvironment

  2013cited by this paper
• PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

  2013cited by this paper
• T cell immunity as a tool for studying epigenetic regulation of cellular differentiation

  2013cited by this paper
• Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody.

  2013cited by this paper
• Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

  2013cited by this paper
• Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma.

  2013cited by this paper
• Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma

  2013cited by this paper
• Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

  2013cited by this paper
• T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

  2013cited by this paper
• Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

  2013cited by this paper
• Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration

  2013cited by this paper
• Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

  2013cited by this paper
• Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.

  2013cited by this paper
• Mutational landscape and significance across 12 major cancer types

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

  2012cited by this paper
• Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

  2012cited by this paper
• An immune-active tumor microenvironment favors clinical response to ipilimumab

  2012cited by this paper
• Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

  2011cited by this paper
• Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

  2010cited by this paper
• Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

  2010cited by this paper
• Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.

  2009cited by this paper
• Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.

  2009cited by this paper
• CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

  2009cited by this paper
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

  2008cited by this paper
• CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

  2008cited by this paper
• Drug resistance and the solid tumor microenvironment.

  2007cited by this paper
• In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients

  2007cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

  2005cited by this paper
• Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus 1

  2003cited by this paper
• Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

  2002cited by this paper
• IFN-gamma production by antigen-presenting cells: mechanisms emerge.

  2001cited by this paper
• IFN-γ production by antigen-presenting cells: mechanisms emerge

  2001cited by this paper
• Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

  1998cited by this paper
• The IFN gamma receptor: a paradigm for cytokine receptor signaling.

  1997influential reference

• Digital spatial profiling of α-PD-1 treated breast cancer bone metastases reveals region-specific signaling and enrichment of immune-suppressive markers

  2026cites this paper
• Incremental prognostic value of immune cell densities beyond clinical parameters in non-small cell lung cancer.

  2026cites this paper
• Inflammatory–Molecular Clusters as Predictors of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer

  2026cites this paper
• Molecular Targets of Cervical Cancer and Its Microenvironment: Advances in Treatment.

  2026cites this paper
• Spatial profiling of the metabolism-immune axis in ovarian cancer

  2026cites this paper
• Integrative Multi‐Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer

  2025cites this paper
• Overcoming tumour resistance in cancer immunotherapy through predictive and pharmacodynamic biomarkers.

  2025cites this paper
• Pan-cancer landscape of cellular senescence heterogeneity reveals associations with prognosis and therapy response

  2025cites this paper
• Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions

  2025cites this paper
• Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

  2025cites this paper
• Efficacy and safety analysis of immune checkpoint inhibitor rechallenge in advanced esophageal squamous cell carcinoma: A retrospective study

  2025influential citation
• Significance of CD8+T cells related gene ITGB2 in prognosis and tumor microenvironment of small cell lung cancer

  2025cites this paper
• Exploring the Role of Cellular Interactions in the Colorectal Cancer Microenvironment

  2025cites this paper
• Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care

  2025cites this paper
• Radiosynthesis and Preclinical Evaluation of [89Zr]Zr-3,4,3-LI(1,2-HOPO)-Durvalumab for Immuno-PET

  2025cites this paper
• Turning cold tumors into hot tumors to ignite immunotherapy

  2025cites this paper
• Quality of Life results and survival outcomes in trials of immunotherapy in advanced cancers: a systematic review and meta-research study.

  2025cites this paper
• Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre‐clinical models

  2025influential citation
• Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

  2025cites this paper
• Multisequence MRI-driven assessment of PD-L1 expression in non-small cell lung cancer: a pilot study

  2025cites this paper
• Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches

  2025cites this paper
• Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial

  2025cites this paper
• Proportional Correlation Between Systemic Inflammation Response Index and Gastric Cancer Recurrence Time: A Retrospective Study

  2025cites this paper
• Innate immunity in tumour immunoediting and immunosurveillance

  2025cites this paper
• Single Cell Spatial Transcriptomics Reveals Immunotherapy-Driven Bone Marrow Niche Remodeling in AML

  2025cites this paper
• DPH2 is a biomarker associated with cell death, immunity and prognosis based on pan-cancer analysis

  2025cites this paper
• Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy

  2025cites this paper
• Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade

  2025cites this paper
• PD-1/PD-L1 Blockade Based Immunotherapy in Cancer Treatment

  2025cites this paper
• The contribution of automated cytometry in immuno-oncology.

  2025cites this paper
• Prognostic impact of immune phenotype in oral squamous cell carcinoma.

  2025cites this paper
• Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy

  2025cites this paper
• Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy

  2025cites this paper
• Prognostic factors and overall survival for recurrent and metastatic head and neck squamous cell carcinoma: a multicenter retrospective analysis.

  2025cites this paper
• Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy

  2025cites this paper
• Efficacy and safety of first-line immune checkpoint inhibitors in patients with PD-L1 <1% metastatic non-small-cell lung cancer – implications for daily clinical practice

  2025cites this paper
• Tumor Microenvironment: Recent Advances in Immunotherapies of Pancreatic Cancer

  2025cites this paper
• Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)

  2025cites this paper
• New power in cancer immunotherapy: the rise of chimeric antigen receptor macrophage (CAR-M)

  2025cites this paper
• C‐X‐C chemokine receptor CXCR4 mediates diurnal changes in the aggregation and dispersion of CD8 + T cells within the tumor microenvironment

  2025influential citation
• HMGA2 links morphological evolution and microenvironment dynamics to systemic therapy response in clear cell renal cell carcinoma

  2025cites this paper
• Immune Modulation in Cancer: The Role of Tumor‐Treating Fields (TTFields)

  2025cites this paper
• Retinal Sensitivity Loss and Beyond in KCNV2-Related Retinopathy: The First Genetically Confirmed Case in Türkiye

  2025cites this paper
• One Step Ahead: Preventing Tumor Adaptation to Immune Therapy.

  2025cites this paper
• CXCL9 and CXCL13 shape endometrial cancer immune‐activated microenvironment via tertiary lymphoid structure formation

  2025cites this paper
• Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression

  2025cites this paper
• Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy

  2025cites this paper
• [68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors

  2025cites this paper
• Biomarkers associated with response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer

  2025cites this paper
• Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification

  2025cites this paper
• Nano-Based Strategies Aiming at Tumor Microenvironment for Improved Cancer Therapy.

  2025cites this paper
• Identification of cold tumor induction–related markers in pancreatic cancer and the clinical implication of PCDH7

  2025cites this paper
• Lymph node-targeted delivery of Lonicera japonica thunb. polysaccharides for enhancing antitumor immunotherapy

  2025cites this paper
• YY2 Serves as a Novel Prognostic Biomarker Correlated with Immune Microenvironment and Glycolysis in Esophageal Carcinoma

  2025cites this paper
• Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors

  2025cites this paper
• Bioactive metallic nanoparticles for synergistic cancer immunotherapy

  2025cites this paper
• Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer.

  2025cites this paper
• Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer

  2025cites this paper
• HDAC1 Mediates Immunosuppression of the Tumor Microenvironment in Non-Small Cell Lung Cancer

  2025influential citation
• Single-cell sequencing reveals tumor microenvironment features associated with the response to neoadjuvant immunochemotherapy in oral squamous cell carcinoma

  2025cites this paper
• The solid tumor microenvironment and related targeting strategies: a concise review

  2025cites this paper
• Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy.

  2025cites this paper
• Correlation analysis of mitochondrial DNA maintenance-related genes with HCC prognosis, tumor mutation burden and tumor microenvironment features

  2025cites this paper
• Bioinspired ruthenium-manganese-oxygen complex for biocatalytic and radiosensitization therapies to eradicate primary and metastatic tumors

  2025cites this paper
• A novel model for predicting immunotherapy response and prognosis in NSCLC patients

  2025cites this paper
• Comparison of Histologic Parameters and Predictive Gene Signatures in Clear Cell Renal Cell Carcinoma Response to Systemic Therapy

  2025cites this paper
• Advances in Multimodal Imaging Techniques for Evaluating and Predicting the Efficacy of Immunotherapy for NSCLC

  2025cites this paper
• Breaking down physical barriers: strategies to improve lymphocyte infiltration for effective neoantigen-based therapies

  2025cites this paper
• Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML

  2025cites this paper
• T cells in cancer: mechanistic insights and therapeutic advances

  2025cites this paper
• Chemotherapy modulates PD-L1 expression and its combination with immune checkpoint blockade requires precision.

  2025cites this paper
• Integrating tumor macroenvironment, microenvironment and mechanobiology with organoid and organ-on-a-chip models for lung cancer immunotherapy.

  2025cites this paper
• Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects

  2025cites this paper
• Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study.

  2025cites this paper
• NRF2 activation in cancer cells suppresses immune infiltration into the tumor microenvironment

  2025cites this paper
• Case Report: Prognostic evaluation of immunotherapy in two patients with SMARCA4-UT using TCR as a new marker

  2025cites this paper
• Prevalence, immune checkpoint expression and spatial interplay of immune cells is linked to favourable tumor phenotype in 4915 human carcinomas.

  2025cites this paper
• Distinct Immunosuppressive Tumor Microenvironment in Gastric Cancer With Peritoneal Metastasis

  2025cites this paper
• Immune archetypes TIME classification system for nasopharyngeal carcinoma: A new direction for precision immunotherapy.

  2025cites this paper
• Intratumoral heterogeneity and immunotherapy resistance: clinical implications.

  2025cites this paper
• A conserved subset of cold tumors responsive to immune checkpoint blockade

  2024cites this paper
• Physiological markers for immunotherapeutics: a review

  2024cites this paper
• The role of tumor types in immune-related adverse events

  2024cites this paper
• Targeting Cancer: Microenvironment and Immunotherapy Innovations

  2024cites this paper
• The clinical significance of signal regulatory protein alpha expression in the immune environment of gastric cancer

  2024cites this paper
• ALK-Rearranged Renal Cell Carcinoma: A Study of Three Cases With Clinicopathologic Features and Effect of Postoperative Adjuvant Immunotherapy.

  2024cites this paper
• Coley’s Toxin to First Approved Therapeutic Vaccine—A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment

  2024cites this paper
• Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications

  2024cites this paper
• Advances in Immune Checkpoint Therapy in Hepatocellular Carcinoma.

  2024cites this paper
• Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies

  2024cites this paper
• Research Progress on Reshaping the Tumor Immune Microenvironment to Enhance the Effectiveness of Immunotherapy

  2024cites this paper
• Hepatocellular Carcinoma Immune Microenvironment Analysis: A Comprehensive Assessment with Computational and Classical Pathology.

  2024cites this paper
• Harnessing nucleotide metabolism and immunity in cancer: a tumour microenvironment perspective

  2024cites this paper
• Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma

  2024cites this paper
• Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer

  2024influential citation
• Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach

  2024cites this paper
• Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy

  2024cites this paper
• Immunoarchitectural Pattern and Its Potential Prognostic Value in Mucoepidermoid Carcinoma

  2024cites this paper
• Genomic profiling and immune phenotyping of neuroendocrine bladder cancer.

  2024cites this paper
• Application of Newcastle Disease Virus in the Treatment of Human and Canine Mammary Cancer

  2024cites this paper